{"disease":{"id":"hepatitis-a-virus","name":"hepatitis a virus"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03944447","title":"Outcomes Mandate National Integration With Cannabis as Medicine","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":200000,"lead_sponsor_name":"OMNI Medical Services, LLC","has_results":false},{"nct_id":"NCT06596213","title":"Hepatitis Inequalities Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT07358910","title":"Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Institut Pasteur du Cambodge","has_results":false},{"nct_id":"NCT07388979","title":"MAGIA H3S Point of Care Test Performance for HIV, HBV, HCV, and Syphilis Screening in Pregnant Women in DR Congo","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":7500,"lead_sponsor_name":"Gardiens de Vies","has_results":false},{"nct_id":"NCT07258251","title":"Strengthening Hepatitis B Screening, Linkage to Care and Long-Term Monitoring in Phichit Province, Thailand: A Birth Bohort Approach","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":6000,"lead_sponsor_name":"The Task Force for Global Health","has_results":false},{"nct_id":"NCT03870061","title":"Evaluation of an Infant Immunization Encouragement Program in Nigeria","phase":"NA","overall_status":"COMPLETED","enrollment_count":5187,"lead_sponsor_name":"GiveWell","has_results":false},{"nct_id":"NCT05394623","title":"Prevalence and Burden of Hepatitis D Virus Infection in China Through Preoperative Examination Test (Predict Study)","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT03415334","title":"Effect of Implementation Of Outreach Behavioral Change Program for HCV Elimination","phase":"NA","overall_status":"COMPLETED","enrollment_count":3575,"lead_sponsor_name":"National Research Centre, Egypt","has_results":false},{"nct_id":"NCT07038863","title":"Community Screening and Management of Hepatitis B, C and Delta in the Mongolian Population Living in France","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT07274345","title":"Prevalence and Risk Factors of Antiviral Resistance in Egyptian HBV Patients","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Amira Mohamed Zidan","has_results":false},{"nct_id":"NCT00689390","title":"Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063)","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":1954,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT06786429","title":"Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health.","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":1800,"lead_sponsor_name":"Eunice Dube","has_results":false},{"nct_id":"NCT05361603","title":"Acceptability of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users in Non-conventional Structures","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"University Hospital, Limoges","has_results":false},{"nct_id":"NCT05657106","title":"Kentucky Outreach Service Kiosk (KyOSK): Reducing HIV, HCV, and Overdose Risk","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":752,"lead_sponsor_name":"April M Young","has_results":false},{"nct_id":"NCT02243293","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":694,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT04429295","title":"Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":460,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT04363411","title":"Reaching Out to the UNdiagnosed People Infected With Blood Borne Viral Infections","phase":"NA","overall_status":"COMPLETED","enrollment_count":425,"lead_sponsor_name":"Hasselt University","has_results":false},{"nct_id":"NCT03719313","title":"Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":407,"lead_sponsor_name":"Eiger BioPharmaceuticals","has_results":false},{"nct_id":"NCT01939197","title":"A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":318,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT04768517","title":"HCV Reinfection in in HIV/HCV-coinfected Patients Achieving SVR by Antiviral Therapy","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT02707952","title":"A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":295,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT04850950","title":"Tenofovir Alafenamide to Prevent Perinatal Transmission of Hepatitis B","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":240,"lead_sponsor_name":"The First Affiliated Hospital of Zhengzhou University","has_results":false},{"nct_id":"NCT03369327","title":"Sofosbuvir and Daclatasvir for Treating Hepatitis C in 200 Patients Co-infected With Human Immunodeficiency Virus","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":232,"lead_sponsor_name":"Tehran University of Medical Sciences","has_results":false},{"nct_id":"NCT03250910","title":"Generic VEL/SOF With or Without RBV for HIV/HCV Coinfected Patients","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":228,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT06859619","title":"Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-borne Diseases","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":183,"lead_sponsor_name":"University Hospital, Montpellier","has_results":false},{"nct_id":"NCT02582632","title":"A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":166,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT03855176","title":"Effectiveness of Booster With 1 or 2 Doses of HAV Vaccine Among HIV-infected Patients","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":153,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT02738138","title":"A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":153,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT05070364","title":"Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"Eiger BioPharmaceuticals","has_results":false},{"nct_id":"NCT02103439","title":"An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":140,"lead_sponsor_name":"Biocad","has_results":true},{"nct_id":"NCT02723084","title":"A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":136,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT03453346","title":"Safety and Efficacy of Generic Sofosbuvir and Ribavirin for Treatment-naive Genotype 2 Chronic Hepatitis C","phase":"NA","overall_status":"COMPLETED","enrollment_count":136,"lead_sponsor_name":"Kawin Technology Share-holding Co., Ltd.","has_results":false},{"nct_id":"NCT01907230","title":"Entecavir for Biological Agents Associated HBV Reactivation in Inflammatory Arthritis Patients","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":115,"lead_sponsor_name":"Taipei Veterans General Hospital, Taiwan","has_results":false},{"nct_id":"NCT05861674","title":"A Study to Assess Efficacy and Safety of HH-003 Injection in Subjects With Chronic Hepatitis Delta Virus Infection","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":101,"lead_sponsor_name":"Huahui Health","has_results":false},{"nct_id":"NCT02692703","title":"A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT02442284","title":"A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":99,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT02613403","title":"Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":94,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT02207088","title":"Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT07032610","title":"Long-term Immunogenicity of L-HAV Vaccine Among Healthy Thai Children and Adolescents","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Chiang Mai University","has_results":false},{"nct_id":"NCT02817451","title":"DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":53,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT06942962","title":"Immunity With Acute Hepatits A","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT06740474","title":"A Study to Assess the Safety, Tolerability and Pharmacokinetics of ABI-6250 in Healthy Participants","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Assembly Biosciences","has_results":false},{"nct_id":"NCT02219477","title":"A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT06978621","title":"Immunogenicity and Safety of I-HAV in Healthy Thai Children and Adolescents Lacking Protective Antibody After L-HAV","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Chiang Mai University","has_results":false},{"nct_id":"NCT06661148","title":"Study of EPI-003 in Select Nucleos(t)Ide Analogue-Treated, Chronic Hepatitis B Patients","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":36,"lead_sponsor_name":"Epigenic Therapeutics, Inc","has_results":false},{"nct_id":"NCT04596475","title":"Prevention of Transmission of Hepatitis C Virus (HCV) From HCV-Viremic Organ Donor","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"University of California, San Diego","has_results":false},{"nct_id":"NCT04019717","title":"Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Atea Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT02881762","title":"Maraviroc Efficacy for Hepatitis C","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"University of Maryland, Baltimore","has_results":true},{"nct_id":"NCT06780579","title":"Expanded Access for Bulevirtide","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Gilead Sciences","has_results":false}],"total":49},"guidelines":[],"source":"Drug Landscape verified database"}